Legal & General Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-51,153
| Closed | -$1.97M | – | 3440 |
|
|
2023
Q2 | $1.97M | Buy |
51,153
+28,129
| +122% | +$722K | ﹤0.01% | 1944 |
|
|
2023
Q1 | $533K | Buy |
23,024
+6,677
| +41% | +$159K | ﹤0.01% | 2303 |
|
|
2022
Q4 | $428K | Buy |
16,347
+768
| +5% | +$17K | ﹤0.01% | 2374 |
|
|
2022
Q3 | $306K | Buy |
15,579
+960
| +7% | +$19.3K | ﹤0.01% | 2471 |
|
|
2022
Q2 | $256K | Buy |
14,619
+11,216
| +330% | +$176K | ﹤0.01% | 2546 |
|
|
2022
Q1 | $56K | Buy |
3,403
+314
| +10% | +$4.27K | ﹤0.01% | 2988 |
|
|
2021
Q4 | $50K | Buy |
3,089
+383
| +14% | +$5.45K | ﹤0.01% | 3035 |
|
|
2021
Q3 | $35K | Buy |
2,706
+196
| +8% | +$2.58K | ﹤0.01% | 3080 |
|
|
2021
Q2 | $35K | Buy |
2,510
+1,075
| +75% | +$17.2K | ﹤0.01% | 3078 |
|
|
2021
Q1 | $22K | Sell |
1,435
-119
| -8% | -$1.94K | ﹤0.01% | 3108 |
|
|
2020
Q4 | $25K | Sell |
1,554
-2
| -0.1% | -$30 | ﹤0.01% | 3007 |
|
|
2020
Q3 | $19K | Sell |
1,556
-424
| -21% | -$5.68K | ﹤0.01% | 2996 |
|
|
2020
Q2 | $23K | Sell |
1,980
-79
| -4% | -$1.09K | ﹤0.01% | 3015 |
|
|
2020
Q1 | $27K | Sell |
2,059
-316
| -13% | -$3.74K | ﹤0.01% | 2811 |
|
|
2019
Q4 | $14K | Sell |
2,375
-117
| -5% | -$636 | ﹤0.01% | 3256 |
|
|
2019
Q3 | $13K | Hold |
2,492
| – | – | ﹤0.01% | 3235 |
|
|
2019
Q2 | $22K | Hold |
2,492
| – | – | ﹤0.01% | 3168 |
|
|
2019
Q1 | $50K | Sell |
2,492
-3,569
| -59% | -$62.2K | ﹤0.01% | 2710 |
|
|
2018
Q4 | $80K | Buy |
6,061
+1,237
| +26% | +$24.7K | ﹤0.01% | 2523 |
|
|
2018
Q3 | $177K | Hold |
4,824
| – | – | ﹤0.01% | 2362 |
|
|
2018
Q2 | $169K | Buy |
4,824
+377
| +8% | +$14.5K | ﹤0.01% | 2336 |
|
|
2018
Q1 | $206K | Buy |
4,447
+2,281
| +105% | +$83.5K | ﹤0.01% | 2288 |
|
|
2017
Q4 | $82K | Hold |
2,166
| – | – | ﹤0.01% | 2680 |
|
|
2017
Q3 | $116K | Buy |
2,166
+94
| +5% | +$5.58K | ﹤0.01% | 2567 |
|
|
2017
Q2 | $118K | Buy |
2,072
+209
| +11% | +$10.5K | ﹤0.01% | 2519 |
|
|
2017
Q1 | $100K | Sell |
1,863
-28
| -1% | -$1.58K | ﹤0.01% | 2540 |
|
|
2016
Q4 | $108K | Buy |
1,891
+724
| +62% | +$43.8K | ﹤0.01% | 2517 |
|
|
2016
Q3 | $68K | Hold |
1,167
| – | – | ﹤0.01% | 2385 |
|
|
2016
Q2 | $63K | Buy |
+1,167
| New | +$70.9K | ﹤0.01% | 2350 |
|
Legal & General Group's KDNY Position: Q3 2023 in Review
Legal & General Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 51,153 shares — an estimated $1.97M sold.
Legal & General Group first reported a position in KDNY in Q2 2016 and held it in 29 quarters. The position peaked at $1.97M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Legal & General Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Legal & General Group sold 51,153 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.97M.
- Legal & General Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2016 and held it in 29 quarters.
- Legal & General Group's Chinook Therapeutics, Inc. Common Stock position peaked at $1.97M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Legal & General Group's 13F filing for Q3 2023, filed 14 Nov 2023.